Furthermore, a prospective study by Mone et al. (2022) provided significant evidence for the positive impact of SGLT-2 (EMP) inhibitors on cognitive function in older patients with diabetes [255]. This evidence concerns the gene SLC5A2 and diabetes mellitus.